Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study-Reference-Cited by-同舟云学术

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Published:2020-09 Issue:10254 Volume:396 Page:839-852
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Abramson Jeremy S,Palomba M Lia,Gordon Leo I,Lunning Matthew A,Wang Michael,Arnason Jon,Mehta Amitkumar,Purev Enkhtsetseg,Maloney David G,Andreadis Charalambos,Sehgal Alison,Solomon Scott R,Ghosh Nilanjan,Albertson Tina M,Garcia Jacob,Kostic Ana,Mallaney Mary,Ogasawara Ken,Newhall Kathryn,Kim Yeonhee,Li Daniel,Siddiqi Tanya

Publisher

Elsevier BV

Subject

General Medicine

Reference39 articles.

1. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

2. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

3. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study;Van Den Neste;Bone Marrow Transplant,2016

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

5. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era;Thanarajasingam;Br J Haematol,2018

Cited by 1481 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies;Recent Patents on Anti-Cancer Drug Discovery;2024-12

2. FDG-PET/CT Imaging in Chimeric Antigen Receptor–Engineered T-Cell Treatment in Patients with B-Cell Lymphoma;PET Clinics;2024-10

3. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy;Blood Advances;2024-09-24

4. Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals;Future Oncology;2024-09-13

5. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies;Blood;2024-09-12